
Alkem Laboratories Analyst Review 2027: Sales Up 14%, Profit Down 12%, and a Tax Rate That Tripled
Updated: 17 Nov 2026 • 2:10 pm
Posted by:

Alkem Laboratories Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹5,136
- 52-Week High / Low: ₹5,933.50 / ₹4,811
- Market Capitalisation: ₹61,456 crore
- P/E Ratio vs Industry P/E: 29.4 vs 40.7
- Latest Quarter (Q2 FY27) Revenue: ₹4,552 crore (consolidated)
- Latest Quarter (Q2 FY27) Net Profit: ₹675 crore (consolidated)
Quick Answer: The Alkem Laboratories analyst review 2027 shows a business growing faster than its profit line. Q2 FY27 revenue rose 13.8% to ₹4,552 crore and EBITDA rose 11.3% to ₹1,025 crore, but profit after tax fell 11.7% to ₹675 crore because the effective tax rate jumped to about 33% from 13%. Brokers are divided: Nomura (Buy, ₹6,890) sits at the top, Motilal Oswal (Neutral, ₹5,770) and ICICI Securities (Neutral, ₹5,840) in the middle, and BOBCAPS (Sell, ₹4,638) at the bottom. At ₹5,136, the stock trades closer to its 52-week low than its high.
The Alkem Laboratories analyst review 2027 begins with a quarter where the operating story and the reported profit pointed in opposite directions. For anyone following the Alkem Laboratories share price target 2027, the September 2026 quarter, reported on 12 November, showed revenue up 13.8% and EBITDA up 11.3%, while net profit fell 11.7% because of a much higher tax charge.
Alkem Laboratories closed at ₹5,136 on 16 November 2026, about 13% below its 52-week high of ₹5,933.50 and just 7% above its low of ₹4,811. This Alkem Laboratories analyst review 2027 covers the brokerage spread, the quarter, how the company earns, and the issues that will shape the Alkem Laboratories stock outlook 2027.
Click Here – Get Free Investment Predictions
Brokerage Views in the Alkem Laboratories Analyst Review 2027
The table lists targets traced to dated reports. None was issued after the 12 November results, so these are the latest verified positions.
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| Nomura | Buy | ₹6,890 | May 2026 |
| ICICI Securities | Neutral | ₹5,840 | May 2026 |
| Motilal Oswal Financial Services | Neutral | ₹5,770 | August 2026 |
| Choice Institutional Equities | Add | ₹5,755 | May 2026 |
| BOB Capital Markets (BOBCAPS) | Sell | ₹4,638 | May 2026 |
Motilal Oswal's August note captures the middle view. It called Q1 FY27 a strong margin-led beat with good momentum in chronic therapies, but said investments in new businesses would weigh on FY27 earnings and left limited upside at 27 times forward earnings. Nomura is more optimistic, pointing to double-digit India growth and a lower tax rate in earlier guidance. BOBCAPS sees the stock as already fully valued.
So the Alkem Laboratories analyst review 2027 spans about 10% downside to 34% upside. The tax surprise in Q2 is likely to be the main topic of any revised brokerage notes.
Q2 FY27 Results in the Alkem Laboratories Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from Operations | ₹4,552 crore | ₹4,001 crore | +13.8% |
| EBITDA | ₹1,025 crore | ₹921 crore | +11.3% |
| Profit After Tax (after minority) | ₹675 crore | ₹765 crore | -11.7% |
| India Sales | ₹3,028 crore | ₹2,766 crore | +9.5% |
| International Sales | ₹1,454 crore | ₹1,189 crore | +22.3% |
| Effective Tax Rate | about 33.2% | about 13.0% | +20 pts |
The tax line explains almost everything. A jump in the effective tax rate to about 33% from 13% turned EBITDA growth into a profit decline. Alkem had earlier benefited from lower tax on certain operations, so the step-up hurts comparisons for several quarters. There was also a one-time gain of about ₹35 crore in the quarter.
The underlying business was healthy. In the Alkem Laboratories analyst review 2027 numbers, chronic therapies grew 22.4%, well ahead of Indian pharma market growth of about 16%. US sales rose 2.4% to ₹783 crore despite pricing pressure, and non-US international sales jumped 58% to ₹671 crore, or about 29% without the Occlutech acquisition.
How Alkem Laboratories Makes Money
- India branded generics: about 68% of sales. Alkem is a leader in acute therapies such as anti-infectives and pain management, and is growing in chronic areas like diabetes and cardiology.
- United States: generic medicines sold through distributors, a market with steady price erosion.
- Other international markets: branded and generic sales in Latin America, Europe, Asia and Africa, now including Occlutech's medical devices.
- New businesses: biosimilars through the Enzene subsidiaries and contract development and manufacturing.
India is the profit engine, which is why the Alkem Laboratories analyst review 2027 debate often centres on whether domestic growth can beat the market by enough.
Growth Triggers in the Alkem Laboratories Analyst Review 2027
- Chronic portfolio: growth of 22.4% in Q2 shows Alkem gaining share in higher-value therapies.
- Non-US exports: 58% growth, helped by Occlutech, diversifies away from the US.
- Margin guidance: management guided an EBITDA margin of 20% to 21% for FY27, and Q2 came in at about 22.5%.
- Biosimilars: Enzene is a longer-term option that could lift growth once launches scale.
- New leadership: Dr Amrut Naik took over as CEO, and the board appointed a new CFO with the Q2 results.
Alkem is also a member of the Nifty Pharma index, so sector flows affect its price.
Key Risks in the Alkem Laboratories Analyst Review 2027
- Higher tax: a tax rate near 33% will keep profit growth below EBITDA growth until the base adjusts.
- India growth: 9.5% domestic growth trailed the market's 16%, mainly because acute therapies were slower.
- US pricing: 2.4% growth in the US shows continued price erosion.
- New business costs: Motilal Oswal expects investments in biosimilars and other new areas to depress FY27 earnings.
- Leadership transition: a new CEO and CFO in the same year bring execution risk.
Compare Alkem Laboratories With Pharma Peers on the Univest Screener
Alkem Laboratories Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (16 Nov 2026 close) | ₹5,136 |
| 52-Week High / Low | ₹5,933.50 / ₹4,811 |
| Market Capitalisation | ₹61,456 crore |
| P/E (TTM) vs Industry | 29.4 vs 40.7 |
| Price to Book | 4.13 |
| Book Value per Share | ₹1,243 |
| Return on Equity | 13.91% |
| Debt to Equity | 0.16 |
| Dividend Yield | 1.03% |
| FY26 Revenue / Net Profit | ₹15,296 crore / ₹2,353 crore |
The P/E of about 29 is below the pharma industry average of about 41, which is one reason the Alkem Laboratories analyst review 2027 shows more Neutral and Add calls than Sell calls.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 51.20% | 49.70% | -1.50 pts |
| Foreign Institutions (FII) | 9.48% | 10.32% | +0.84 pts |
| Domestic Institutions (DII) | 21.93% | 22.82% | +0.89 pts |
| Public | 17.40% | 17.15% | -0.25 pts |
The promoter group, the Singh family, cut its holding to just under 50%, while both foreign and domestic institutions added. Promoter selling of this size is not unusual for a family-run company, but it is worth tracking alongside the leadership change.
What to Watch After the Alkem Laboratories Analyst Review 2027
- Tax guidance: management's view on the FY27 and FY28 effective tax rate.
- India growth versus market: management had aimed for 100 to 150 basis points above market growth.
- Margin delivery: whether the 20% to 21% FY27 margin guide is raised.
- Biosimilar progress: launches and partnerships at Enzene.
- Revised targets: fresh notes that will reset the Alkem Laboratories share price target 2027 range.
Final Word on the Alkem Laboratories Analyst Review 2027
The Alkem Laboratories analyst review 2027 separates a healthy operating quarter from a disappointing profit line. Revenue and EBITDA grew at double digits, chronic therapies and exports were strong, and margins beat guidance. A tax rate that rose to about 33% is what pushed profit down.
Brokers were already split before the results, from ₹4,638 to ₹6,890. With the stock near the lower end of its range and a P/E below the industry, the Alkem Laboratories stock outlook 2027 will depend on whether India growth recovers and tax clarity arrives. Univest does not give a buy or sell call on the stock.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Alkem Laboratories analyst review 2027 show?
It shows Q2 FY27 revenue up 13.8% to ₹4,552 crore and EBITDA up 11.3% to ₹1,025 crore. Profit after tax fell 11.7% to ₹675 crore because the effective tax rate rose to about 33%. Brokerage views range from Sell to Buy.
What is the Alkem Laboratories share price target 2027 from brokerages?
Nomura has a Buy with ₹6,890, ICICI Securities a Neutral with ₹5,840 and Choice an Add with ₹5,755, all from May 2026. Motilal Oswal has a Neutral with ₹5,770 from August 2026, and BOBCAPS a Sell with ₹4,638. Against ₹5,136, the range runs from about 10% downside to 34% upside.
Why did profit fall in the Alkem Laboratories analyst review 2027 quarter?
The effective tax rate jumped to about 33.2% from about 13.0% a year earlier. That turned 11.3% EBITDA growth into an 11.7% profit decline. The quarter also included a one-time gain of about ₹35 crore.
How did India sales perform in the Alkem Laboratories analyst review 2027?
India sales rose 9.5% to ₹3,028 crore and made up about 68% of total sales. Chronic therapies grew 22.4%, well above market growth of about 16%. Slower acute therapies held back overall domestic growth.
Is Alkem Laboratories expensive, according to the Alkem Laboratories analyst review 2027?
Alkem trades at a P/E of about 29.4, below the pharma industry figure of about 40.7. Its price to book is 4.13 and return on equity is 13.91%. Debt to equity of just 0.16 adds balance sheet comfort.
What risks does the Alkem Laboratories analyst review 2027 highlight?
A higher tax rate, India growth that trailed the market and US price erosion are the main risks. Motilal Oswal expects new-business investments to weigh on FY27 earnings. The company also has a new CEO and a new CFO in the same year.
What should investors track after the Alkem Laboratories analyst review 2027?
Track tax-rate guidance, India growth against the market and delivery on the 20% to 21% margin guide. Biosimilar progress at Enzene is a longer-term factor. Fresh brokerage notes after the 12 November 2026 results will update the target range.
Recent Articles

Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
17 November 2026

Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
17 November 2026

AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
17 November 2026

A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
63 moons technologies Analyst Review 2027: Cyber Arm Lifts Guidance to ₹600 Crore, But the Group Still Loses Money
Popular this week
5Paisa Capital Analyst Review 2027: Revenue Up 12%, Profit Down 26% and an MTF Book Growing 32%

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





